Yes, george says "probably 100% eradication of the hepatitis C viral load!!!" That is a very broad claim. Of course it would be wonderful if t happens!
george, what makes you think this patient could be the first cured? i know the concentration is three times higher but is there something in the literature I overlook that states that this will be the effective dose or are you being overly optimistic? never the less i am impressed by the adherence to the schedule set out for the dosing and review of data by the DSMB.
One share of BNIKF is equal to 1 share of BLT (taking into account difference in exchange value between the american and the australian dollar). BNIKF shares are custodial shares of BLT that were made available on US markets through US brokers so Benitec could access the US capital markets prior to Benitec starting the ADR program. When the ADR program started each ADR included 5 shares of Benitec. Now each ADR is worth 20 shares of Benitec because the ADR ratio was increased by 4 to 1. You still own the same number of shares and the total number of company shares hasn't changed so you own the same proportion of the company that you did before. I don't know why the company changed the number of shares in each ADR so I sent investor relations an email to ask about that. Maybe Benitec is planning further changes in the capital structure of the company because there has been some announcements about them possibly uplisting to an American exchange. In that case they would trade as regular shares one of the US exchanges, maybe NASDAQ instead of being OTC where they are now. There are certain regulatory requirements they would have to meet to be regularly listed on a US exchange. Even if they regularlt listed on a US exchange they would probably remain listed on ASX.
You own the same number of shares its just that are packaged differently, 20 shares for each ADR instead of 5 shares for each ADR. On Schwab as of this message the ask for ADR's is $12.00 and the bid is $11.65.
I see on the Benitec web site that there is an announcement of a change in the number of sponsored shares in each ADR; however, I don't see any announcement of a reverse split of regular shares, which would leave the company with a lesser number of hares , so as far as I can tell there is no difference in the number of regular shares shares this company, just that there will be a different proportion of shares in the ADR's. Can you show me specifically where there is a mention of a reverse split of the regular shares which would leave the company with a smaller amount of regular shares.
Check out their sd-sxRNAi. Glad I sold my shares in this company. Can anyone please tell me why this tech is better than RXII.
Voted no on the stock option plan. Shareholders have put up with enough nonsense from this company with their legacy legal problems and Rabin's tomfoolery. Let them have additional options when they have met target dates and have generated some share price. There's no way sales should be postponed till 2019 when they are already through a successful Phase 1. If Wooton can't make get financing or a joint venture based on selling vision to the blind, maybe he should get a job as a heating oil salesman in Alaska. So far insiders at this company are treating the shareholders as a free lunch. Can't see why Wooton is getting paid more than Doc based on his performance so far, i think Wooton is one of those Wall Street types.
institutional shares have the share price creeping up.
By Dr Lu, one of our scientists, search on touch opthalmology for
"Development of a Stem Cell Therapy for Glaucoma"
Glaucoma is one of the pathologies listed on Ocata web site as already mentioned. Hat tip to investor stem cell.
You can't get much cheaper than injection straight through the eyeball to the back of the eye. This isn't like taking aspirin for a headache. You need to read up on the pathology and the tech.
Absolutely, the more IP they get under their belt their value increases quantum fold. There very well can be more than one suitor because with the number of patents they are stacking up, there is very big development potential. This is a company with a lot of ground floor opportunities and a patent machine that seems to be operating at peak efficiency.
confirmed by completed Phase 1 clinical trial and by articles published in The Lancet, peer reviewed medical journal. Also the 10-Q has the following paragraph which mentions the "product", so if you are going to refer to the 10-Q you should make sure it says what you claim, for those of you who say there is no product you are in direct contradiction to the 10-Q. Also, there is no where in the 10-Q any mention of waiting 10 years for sales. Paragraph 1 "OphthalmologyTM therapeutics. The most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, the Company has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The Company’s intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy technologies. The Company has no therapeutic products currently available for sale and does not expect to have any therapeutic products commercially available for sale for a period of years, if at all. These factors indicate that the Company’s ability to continue research and development activities is dependent upon the ability of management to obtain additional financing as required."
If the Phase 2 trials are pivotal trials and are as successful as Phase 1, then I would expect that sales could happen quickly, given the test results and the large un-met need.
NASDAQ now shows 30 institutional buyers and ZERO sold positions!! Nice update. This company will; have plenty of money cause they're selling a lot of shares, now that the word is getting out.
“For the first time a pluripotent stem cell derived therapy is about to enter a pivotal trial for Stargardt’s Disease and phase 2 clinical trials for dry Age Related Macular Degeneration
“These new patents bolster an already robust patent estate. This is important as we continue to invest in the clinical development of these innovative new therapies for macular degeneration,” said Dr. Eddy Anglade, Chief Medical Officer of Ocata. “For the first time a pluripotent stem cell derived therapy is about to enter a pivotal trial for Stargardt’s Disease and phase 2 clinical trials for dry Age Related Macular Degeneration, bringing the possibility of these long awaited therapies that much closer to reality.”